Asset Details
Do you wish to reserve the book?
Safety and pharmacokinetic properties of a new formulation of parenteral artesunate in healthy Thai volunteers
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Safety and pharmacokinetic properties of a new formulation of parenteral artesunate in healthy Thai volunteers
Do you wish to request the book?
Safety and pharmacokinetic properties of a new formulation of parenteral artesunate in healthy Thai volunteers
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Safety and pharmacokinetic properties of a new formulation of parenteral artesunate in healthy Thai volunteers
2024
Overview
Background
Parenteral artesunate is the first-line therapy for severe malaria. Artesunate, in its current formulation, must be prepared immediately before administration by first dissolving in sodium bicarbonate solution and then diluting in saline. A novel solvent for rapid and stable single step reconstitution of artesunate was recently developed showing improved solubility and stability. This study aimed to compare the safety and pharmacokinetic properties of the currently available and newly developed parenteral formulation of artesunate in healthy Thai volunteers.
Methods
This was an open-label, randomized, 4 periods, 4-treatments, 24-sequence, single-dose, cross-over study in 72 male and female healthy Thai volunteers. Frequent pharmacokinetic samples were collected in all volunteers at each dose occasion. Observed concentration–time profiles were analysed with a non-compartmental approach followed by a bioequivalence evaluation.
Results
Both intramuscular and intravenous administrations of the new parenteral formulation of artesunate were safe and well-tolerated, with no additional safety signals compared to the currently used formulation. The pharmacokinetic properties of artesunate and its active metabolite, dihydroartemisinin, were well-characterized, and showed rapid conversion of artesunate into dihydroartemisinin. Intramuscular administration of the newly formulated artesunate resulted in almost complete bioavailability of dihydroartemisinin. The pharmacokinetic properties were similar between the old and new formulation.
Conclusions
The new and more easily prepared formulation of artesunate was safe and well-tolerated, with similar pharmacokinetic properties compared to the currently used formulation. Dihydroartemisinin, the active metabolite responsible for the majority of the anti-malarial effect, showed equivalent exposure after both intravenous and intramuscular administration of artesunate, suggesting that both routes of administration should generate comparable therapeutic effects.
Trial registration
: The study was registered to clinicaltrials.gov (#TCTR20170907002).
Publisher
BioMed Central,BMC
Subject
/ Adult
/ Antimalarials - administration & dosage
/ Antimalarials - adverse effects
/ Antimalarials - pharmacokinetics
/ Artemisinins - administration & dosage
/ Artemisinins - adverse effects
/ Artemisinins - pharmacokinetics
/ Artesunate - administration & dosage
/ Artesunate - pharmacokinetics
/ Biomedical and Life Sciences
/ Female
/ Humans
/ Malaria
/ Male
/ Thailand
